Ardent Health (ARDT) Q3 2024: Margin Expands 60bps as Outpatient Growth and Cost Controls Accelerate

2024-11-07 | By EarningsIQ Research

Ardent Health’s third quarter delivered accelerating admissions, margin expansion, and visible execution on outpatient and cost initiatives, even as payer friction and service line shifts persisted. Management’s confidence in multi-year EBITDA margin targets and a raised 2024 outlook signals a durable volume and efficiency story—with further upside tied to regulatory programs and ambulatory M&A. Investors should watch operational leverage and payer dynamics as the company leans into its joint venture model and tech-driven care delivery.

Summary

• Margin Expansion Outpaces Peer Set: Service line optimization and supply chain initiatives drive visible EBITDA margin gains.
• Outpatient and Ambulatory Push Gains Traction: New urgent care centers and ASC focus broaden patient funnel and downstream volumes.
• Multi-Year Growth Levers Remain Intact: Regulatory DPP adoption and disciplined M&A underpin management’s raised guidance and confidence.

Business Overview

Ardent Health Partners operates acute care hospitals, outpatient centers, and physician clinics across midsize urban markets, generating revenue primarily from inpatient and outpatient services reimbursed by commercial insurers, government payers, and health exchanges. The company’s joint venture model—majority ownership with academic and nonprofit partners—enables access to regional brands and physician networks while retaining operational control. Key segments include inpatient admissions, outpatient surgeries, and ambulatory care, with a growing focus on urgent care and surgery centers.

Performance Analysis

Ardent’s third quarter saw admissions accelerate to 6.4% year-over-year growth, outpacing first-half trends and reflecting both demographic tailwinds and operational efficiency gains. Adjusted admissions and total surgeries returned to growth, with the latter reversing prior declines as service line optimization matured. Revenue rose 5.2% (8% excluding non-recurring items), with commercial mix improving and Medicaid volumes declining due to redeterminations.

Adjusted EBITDA grew 15% year-over-year, lifting margin before non-controlling interest by 60 basis points to 10.9%. Supply expense as a percent of revenue improved 70 basis points, and contract labor normalized further, aided by better nursing retention and cost discipline. Professional fees rose, reflecting higher physician subsidies and revenue cycle outsourcing, while equity-based compensation and capital spending ticked up post-IPO. Cash flow remained solid, with $563 million in cash and available liquidity of $851 million supporting M&A ambitions and leverage targets.

• Volume Acceleration: Admissions and adjusted admissions both outpaced first-half growth, driven by operational improvements and transfer center efficiencies.
• Service Line Mix Shift: Strategic reduction in lower-margin lines (e.g., ENT) and growth in higher-acuity areas (orthopedics) improved case mix and margin profile.
• Cost Levers Deliver: Supply chain initiatives and contract labor normalization contributed to margin expansion, offsetting higher professional fees and compensation costs.

Operational improvements, payer mix shifts, and strategic service line decisions collectively drove both top-line and margin outperformance, supporting management’s upward revision of full-year guidance.

Executive Commentary

Strategic Positioning

1. Joint Venture Model as Growth Engine

Ardent’s joint venture structure—majority control with local health systems and academic partners—remains a cornerstone, enabling access to physician networks, regional brands, and capital-efficient growth. This approach allows operational autonomy while leveraging partner strengths, as seen in recent oncology service transfers and M&A pipeline activity.

2. Ambulatory and Outpatient Expansion

Ambulatory sites of care (urgent care, ASCs, clinics) are increasingly central to Ardent’s market share and patient funnel strategy, with new urgent care centers already driving 30% new-to-Ardent patient rates. This outpatient push is expected to generate incremental downstream hospital and outpatient volumes, and is a focus for future M&A in both existing and new markets.

3. Margin Expansion and Regulatory Levers

Management reiterated its target for mid-teens EBITDA margins over several years, anchored by efficiency initiatives, service line optimization, and regulatory programs like state-directed payments (DPP). New Mexico’s DPP approval and pending CMS sign-off are highlighted as major future margin catalysts, with Oklahoma’s program already contributing in 2024.

4. Technology and AI-Driven Efficiency

Early-stage AI deployments are delivering tangible results, including operating room scheduling optimization (yielding $2.3 million incremental revenue) and virtual call center agents (reducing abandoned calls by 75%). These initiatives are positioned as scalable levers for both cost control and patient experience improvement.

5. Capital Allocation and M&A Discipline

With $851 million in liquidity and leverage trending toward a 3x target, Ardent is positioned for continued M&A—particularly in ambulatory and midsize urban markets. Management emphasizes disciplined capital deployment, synergy realization, and accretive joint venture structures, with a multi-year horizon for integration and value creation.

Key Considerations

This quarter’s results reinforce Ardent’s ability to deliver on both growth and margin levers while navigating payer and regulatory complexity. The following considerations shape the company’s investment thesis and execution outlook:

• Service Line Optimization: Ongoing rationalization of low-margin lines is nearing completion, with higher-acuity growth and outpatient migration reshaping the revenue mix.
• Payer Dynamics and Denials: While denial rates remain elevated, they did not worsen in Q3, and revenue cycle outsourcing is helping mitigate headwinds. Contracting for 2025 remains constructive but more contentious, especially with Medicare Advantage plans.
• Ambulatory Funnel Expansion: Urgent care and ASC growth are driving new patient acquisition and downstream volumes, validating the outpatient-first strategy.
• Regulatory Program Timing: DPP adoption in New Mexico and continued Medicaid redeterminations will be key watchpoints for margin and payer mix in 2025.

Risks

Payer friction remains a persistent risk, particularly as denials stay high and Medicare Advantage negotiations become more contentious. Regulatory timing—especially for DPP approvals—could delay or dilute margin expansion targets, while ongoing Medicaid redeterminations may further shift payer mix. Execution risk exists in scaling ambulatory sites and integrating M&A, and professional fee inflation or labor cost pressures could offset supply chain gains.

Forward Outlook

For Q4 2024, Ardent guided to:

• Adjusted EBITDA of $425 million to $440 million (up from $415 to $435 million).
• Total revenue of $5.8 to $5.875 billion (slightly raised at midpoint).

For full-year 2024, management raised guidance:

• Adjusted admissions growth of 4.5% to 5% (up from 4% to 4.5%).
• Net patient service revenue per adjusted admission growth of 2.6% to 3.3%.

Management highlighted strong volume trends, operational leverage, and regulatory catalysts as drivers for continued EBITDA margin progress. Delayed insurance proceeds from the 2023 cyber event will now be recouped in 2025, but underlying cash flow and capital allocation priorities remain unchanged.

• New Mexico DPP approval is a key 2025 margin catalyst.
• Ambulatory M&A and outpatient scaling remain top priorities.

Takeaways

Ardent’s Q3 confirms its ability to drive both volume and margin growth, leveraging operational discipline and targeted outpatient expansion against a backdrop of payer and regulatory complexity.

• Margin Expansion Is Durable: Supply chain, labor normalization, and service line mix support a multi-year margin improvement trajectory, with DPP programs providing further upside.
• Ambulatory and Outpatient Growth Is Materializing: Early results from urgent care and ASC investments validate the outpatient-first strategy and create a pipeline for downstream hospital utilization.
• Payer and Regulatory Watchpoints Remain: Investors should monitor denial rates, payer mix shifts, and DPP implementation pace as key swing factors for 2025 and beyond.

Conclusion

Ardent Health’s third quarter demonstrates clear progress on volume, margin, and outpatient growth levers, with raised guidance and management conviction in multi-year targets. Execution on cost and ambulatory initiatives, along with regulatory catalysts, position the company for continued outperformance—though payer and policy risks warrant ongoing scrutiny.

Industry Read-Through

Ardent’s accelerating admissions and margin expansion signal a broader rebound in hospital and outpatient demand, particularly in midsize urban markets with favorable demographics. The joint venture model’s success in accessing local brands and physician networks may become a template for other for-profit and nonprofit operators, especially as capital intensity and payer complexity rise. Ambulatory care and urgent care center expansion reflect a sector-wide shift toward consumer-centric, lower-cost care settings, with implications for both hospital utilization and physician alignment. Persistent payer friction and regulatory program timing remain industry-wide risks that will shape margin trajectories and capital allocation for providers across the landscape.

ARDT Healthcare Hospitals Outpatient Margin Ambulatory Joint Venture Regulatory